Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,319 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,657 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05733715 | Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma | recruiting | Early Phase 1 | 30 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT03943173 | Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery | active not recruiting | Early Phase 1 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05495464 | A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma | active not recruiting | Early Phase 1 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06586047 | Breast Cancer PSMA PET | recruiting | Early Phase 1 | 30 | Ahmad ShariftabriziOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT04943913 | Study of GC101 TIL in Brain Glioma (Soochow2) | recruiting | Early Phase 1 | 50 | Shanghai Juncell TherapeuticsINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07741565 | Window Trial of Intratumoral (IT) Neoadjuvant Fluorescently Labelled Nivolumab (nivo800) in Head and Neck Squamous Cell Carcinoma (HNSCC) | not yet recruiting | Early Phase 1 | 18 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Aug 3, 2026 | clinicaltrials |
| NCT07628634 | Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors | recruiting | Early Phase 1 | 25 | University of California, IrvineOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT05023551 | Study of DSP-0390 in Patients With Recurrent High-Grade Glioma | active not recruiting | Early Phase 1 | 39 | Sumitomo Pharma America, Inc.INDUSTRY | 2 | Jul 29, 2026 | clinicaltrials |
| NCT07727668 | Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM) | not yet recruiting | Early Phase 1 | 22 | Shambavi RichardOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT05406700 | Niraparib In Recurrent IDH 1/2 Gliomas | active not recruiting | Early Phase 1 | 16 | Massachusetts General HospitalOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT06228404 | Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPC | active not recruiting | Early Phase 1 | 18 | Shanghai Changzheng HospitalOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT07168785 | [18F]-AraG PET Imaging in LA HNSCC | not yet recruiting | Early Phase 1 | 5 | Indiana UniversityOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07429721 | A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma. | recruiting | Early Phase 1 | 24 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT04504526 | Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases | recruiting | Early Phase 1 | 50 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07101705 | An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies | recruiting | Early Phase 1 | 40 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07205315 | A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia | recruiting | Early Phase 1 | 28 | Grit BiotechnologyINDUSTRY | 1 | Jul 20, 2026 | clinicaltrials |
| NCT02603887 | Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma | active not recruiting | Early Phase 1 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT04857502 | 99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer | recruiting | Early Phase 1 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05464810 | Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer | recruiting | Early Phase 1 | 40 | Emory UniversityOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07712770 | Pilot Radioembolisation Clinical Trial Assessing Safety and Efficacy in Recurrent Glioma(PRECISE) | not yet recruiting | Early Phase 1 | 12 | Olivia Newton-John Cancer Research InstituteOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT05041153 | Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma | active not recruiting | Early Phase 1 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07709299 | Safety and Feasibility of CIK Cell Therapy in HCC After Tumor Resection | not yet recruiting | Early Phase 1 | 6 | Royan InstituteOTHER_GOV | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07389525 | Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study | not yet recruiting | Early Phase 1 | 80 | Indiana UniversityOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06942039 | Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation | recruiting | Early Phase 1 | 15 | C17 CouncilOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07689643 | Safety and Preliminary Efficacy of [177Lu]Lu-RTX-2358 Combined With Immune Checkpoint Inhibitors in Patients With FAP-positive Metastatic Non-Small Cell Lung Cancer | recruiting | Early Phase 1 | 36 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07700121 | PICSTAT Pilot Study for CD8 PET/CT-Guided Lifileucel Treatment in Advanced Melanoma(PICSTAT) | not yet recruiting | Early Phase 1 | 10 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07695012 | CAR-T Cell Therapy for ALL(PAKCAR-ALL) | recruiting | Early Phase 1 | 10 | Dr. Zaineb AkramOTHER_GOV | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07696481 | Clinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute Leukemia(R/R AL) | not yet recruiting | Early Phase 1 | 18 | Zhujiang HospitalOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT03085056 | Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer | active not recruiting | Early Phase 1 | 13 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT04906746 | Ruxolitinib for Cancer Cachexia | active not recruiting | Early Phase 1 | 10 | Tu DanOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06824363 | ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu | recruiting | Early Phase 1 | 34 | University of California, IrvineOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT05852041 | rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance | recruiting | Early Phase 1 | 40 | Northwestern UniversityOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT06813898 | An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN Trial | recruiting | Early Phase 1 | 27 | Northwestern UniversityOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07025226 | Medication Combinations of Dasatinib, Quercetin, Fisetin, Temozolomide, LMP744, and Autologous TLPO Vaccine for the Treatment of Previously Treated Glioma With Residual Disease(Senolytics) | recruiting | Early Phase 1 | 30 | Mayo ClinicOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07210632 | Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG) | recruiting | Early Phase 1 | 38 | Eben RosenthalOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07493447 | Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures | recruiting | Early Phase 1 | 30 | Eben RosenthalOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT06333899 | Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion | recruiting | Early Phase 1 | 15 | Nationwide Children's HospitalOTHER | 6 | Jun 29, 2026 | clinicaltrials |
| NCT07670260 | GoFast CAR T-Cell Therapy for Recurrent Refractory B-Cell Lymphoma | not yet recruiting | Early Phase 1 | 9 | Chinese PLA General HospitalOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT05691010 | A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer | recruiting | Early Phase 1 | 28 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT04161248 | Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma | active not recruiting | Early Phase 1 | 40 | Canadian Cancer Trials GroupNETWORK | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07387666 | Imaging Acetadote Metabolism in Glioblastoma | recruiting | Early Phase 1 | 10 | University of Texas Southwestern Medical CenterOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07662200 | A Simplified Regimen to Prevent Nausea and Vomiting Using Netupitant/Palonosetron in Germ Cell Cancer Patients Receiving Chemotherapy(SPARROW-GC) | not yet recruiting | Early Phase 1 | 10 | Ottawa Hospital Research InstituteOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07460232 | FET PET/CT Imaging To Localize Pituitary Adenomas In Cushing Disease | recruiting | Early Phase 1 | 50 | Mayo ClinicOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07007325 | Evaluation of the Value of [68Ga]Ga-PENTIXAFOR PET-CT in Patients With Metastatic Small Cell Lung Cancer (SCLC)(PASSIFLORE) | not yet recruiting | Early Phase 1 | 15 | Institut Cancerologie de l'OuestOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07655869 | [177Lu]Lu-DOTA-EB-RGD2 Therapy in Patients With Recurrent High-grade Glioma | recruiting | Early Phase 1 | 24 | Beijing Tiantan HospitalOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07657416 | NK521 in the Treatment of Advanced Solid Tumors | not yet recruiting | Early Phase 1 | 18 | Base Therapeutics (Shanghai) Co., Ltd.INDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT06636175 | 64Cu-LLP2A for Imaging Hematologic Malignancies | recruiting | Early Phase 1 | 42 | Washington University School of MedicineOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT05386576 | A Study of Venetoclax in Combination With Chemotherapy to Treat Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) | active not recruiting | Early Phase 1 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07648823 | Dosimetry, Safety, and Efficacy Study of [177Lu]Lu-XT771 in Patients With Recurrent Glioblastoma | recruiting | Early Phase 1 | 5 | Beijing Tiantan HospitalOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT05704283 | 3D Ultrasound for the Imaging of Lymph Nodes in Patients With Breast Cancer | recruiting | Early Phase 1 | 55 | Mayo ClinicOTHER | 1 | Jun 15, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Aug 13, 2026source: clinicaltrials